t
On 26 March 2025, Solvonis Therapeutics plc announced that the European Patent Office confirmed the claims under European Patent Application No. 22730070.4, titled "Therapeutic Aminoindane Compounds and Compositions," are allowable without objection. This application, part of the AWKN-SDN-14 programme (a collaboration with Awakn Life Sciences Corp.), is one of two patent families underpinning the programme's intellectual property portfolio. The EPO has requested a minor amendment to the description.
| Date | 26 Mar 2025 |
| Time | 07:00:02 |
| Category | Corporate updates |
| ID | 0614C |
26 March 2025
Solvonis Therapeutics plc
("Solvonis" or the "Company")
Positive progress on European Patent Application for the AWKN-SDN-14 programme
Solvonis Therapeutics plc (LSE: SVNS), an innovative biotechnology company co-developing therapeutics for mental health disorders, is pleased to report a positive development in the intellectual property position of the AWKN-SDN-14 programme (the "Programme"), its collaboration with Awakn Life Sciences Corp. ("Awakn"). The collaboration is focused on developing next-generation medicine for the treatment of trauma-related mental health disorders, such as Post-Traumatic Stress Disorder ("PTSD"), which affects approximately 13 million adults in the U.S. and which the Company estimates affects 20 million in the US, the UK, and other key EU markets.
Following the Company's announcement on 22 March 2025 regarding preclinical progress and the appointment of Evotec SE to lead in-vitro testing, the European Patent Office (the "EPO") has confirmed that the claims under European Patent Application No. 22730070.4, titled "Therapeutic Aminoindane Compounds and Compositions", are considered allowable with no objections.
This application is one of two patent families underpinning the Programme's intellectual property portfolio and specifically covers key compound classes being advanced through preclinical development. It represents the European leg of a broader international patent strategy for the Programme, with protection also being pursued in other key jurisdictions, including the United States.
In line with standard EPO procedure, the patent examiner has requested a minor amendment to the description to reflect the scope of the allowed claims. Subject to this formality, the application is expected to proceed to grant.
This development provides strong validation of the novelty and inventiveness of the Programme's core compounds and further strengthens its intellectual property position across Europe.
Anthony Tennyson, CEO of Solvonis Therapeutics, commented: "This positive news from the European Patent Office is a strong validation of the scientific and commercial potential of the AWKN-SDN-14 programme. Robust intellectual property is a critical pillar of our and Awakn's strategy, and this progress represents an important step forward as we continue to advance our pipeline toward clinical development across key markets."
Enquiries:
Solvonis Therapeutics plc, Anthony Tennyson, CEO & Executive Director, Email: [email protected]
Allenby Capital (Financial Adviser and Broker) +44 (0) 20 3328 5656
Nick Naylor / Nick Athanas / Ashur Joseph (Corporate Finance) | Guy McDougall (Sales)
About Solvonis Therapeutics plc
Solvonis Therapeutics plc is an innovative biotechnology company focused on developing intellectual property related to the treatment of mental health and substance use disorders, and co-developing therapeutics for mental health disorders. Solvonis' mission is to improve outcomes for individuals suffering from mental health disorders, with an initial focus on trauma-related mental health conditions, such as PTSD. PTSD affected approximately 13 million adults in the U.S. in 2020, with the Company estimating a current affected population of 20 million across the U.S., UK, and key EU markets.
www.solvonis.com | LinkedIn | X (formerly Twitter)